The leading position of Zoetis, Inc. in the APAC animal health market is mainly due to its strong product portfolio and strong distribution network across APAC countries. The company has its presence in 45 countries and sells its products in more than 100 countries. The company is engaged in manufacturing and selling of veterinary pharmaceutical products such as anti-infectives, parasiticides, vaccines, medicated feed additives, and other pharmaceuticals (pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products), and other non-pharmaceuticals (nutritionals as well as products and services in the agribusiness and complementary areas such as biodevices, diagnostics, and genetics). The company primarily focuses on strengthening its animal health product portfolio and aims to maintain customer satisfaction by providing innovative products. In November 2015, Zoetis, Inc. launched Simparica, a chewable ectoparasiticide tablet, to treat and control fleas and ticks in dogs. In order to increase its customer base and maintain its position in the APAC animal health market, the company focuses on various growth strategies such as acquisitions and new product launches. In November 2015, the company acquired PHARMAQ (Norway), one of the leading manufacturers of vaccines for aquaculture.

Merck and Co., Inc. (U.S.) is another significant player in the APAC animal health market. The company has its presence in more than 140 countries with 25 manufacturing sites located in the U.S., Mexico, Brazil, the U.K., France, Germany, Spain, the Netherlands, Germany, Italy, Austria, India, Australia, and New Zealand. The company invested USD 6,704 million, USD 7,180 Million, and USD 7,503 Million on research and development activities in 2015, 2014, and 2013, respectively, to launch new, innovative, and therapeutically effective products.

Sanofi (France) is involved in the research, development, manufacturing, and marketing of healthcare products for humans and animals. The company offers a wide range of animal health products through Merial, the animal health division of the company. The company’s strong presence in more than 100 countries and its vast R&D activities are its major strengths. To maintain its leading position in the animal health market, Merial focuses on delivering effective, novel, safe, and cost-effective animal health products. Merial strategically pursues various growth strategies such as product launches, product acquisitions, acquisitions, and agreements. The company focuses on strengthening its presence in the emerging markets, such as China, India, and Brazil. In 2013, Merial acquired the healthcare business of Dosch Pharmaceuticals Private Limited (India), which helped the company to strengthen its market presence in India. In 2015, the company signed a business exchange agreement with Boehringer Ingelheim (Germany), one of the leading players in animal health products. Under this agreement, Sanofi will exchange its animal health business (Merial) with the consumer healthcare (CHC) business of Boehringer Ingelheim.